Open Access

Quality of life assessment and cost‑utility analysis of initial chemotherapy for patients with non‑Hodgkin's lymphoma: A prospective analysis

  • Authors:
    • Kazuhide Tanaka
    • Masahiro Yasuda
    • Tomoya Tachi
    • Yuta Teshigawara
    • Seiji Inoue
    • Yoko Ino
    • Junichi Kitagawa
    • Yoshihiro Noguchi
    • Tomoaki Yoshimura
    • Hitomi Teramachi
    • Senji Kasahara
  • View Affiliations

  • Published online on: July 11, 2024     https://doi.org/10.3892/ol.2024.14564
  • Article Number: 430
  • Copyright: © Tanaka et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chemotherapy has helped prolong survival in patients with malignant lymphoma, enhancing their quality of life (QOL). Despite the eventual decline in the QOL of patients, the impact of initial chemotherapy remains poorly understood. A prospective patient‑reported QOL survey among patients with malignant lymphoma receiving initial chemotherapy was conducted, targeting those treated at Gifu Municipal Hospital (Gifu, Japan) between January 2021 and December 2022. Surveys were conducted pre‑ and post‑chemotherapy based on the EuroQol 5 dimensions. Drug costs were calculated using official prices and analyzed from the cost payer's perspective via cost‑utility analysis. Among the 60 patients included in the present study, 28 had diffuse large B‑cell lymphoma. Cyclophosphamide, doxorubicin, vincristine, prednisolone ± rituximab therapy was the most common treatment (38 patients) and demonstrated superior cost‑effectiveness due to its lowest cost and change in utility value. Initial chemotherapy for patients with malignant lymphoma generally improved the QOL. Clinical trial registration: UMIN000042868 (registered on December 28, 2020).
View Figures
View References

Related Articles

Journal Cover

September-2024
Volume 28 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tanaka K, Yasuda M, Tachi T, Teshigawara Y, Inoue S, Ino Y, Kitagawa J, Noguchi Y, Yoshimura T, Teramachi H, Teramachi H, et al: Quality of life assessment and cost‑utility analysis of initial chemotherapy for patients with non‑Hodgkin's lymphoma: A prospective analysis. Oncol Lett 28: 430, 2024.
APA
Tanaka, K., Yasuda, M., Tachi, T., Teshigawara, Y., Inoue, S., Ino, Y. ... Kasahara, S. (2024). Quality of life assessment and cost‑utility analysis of initial chemotherapy for patients with non‑Hodgkin's lymphoma: A prospective analysis. Oncology Letters, 28, 430. https://doi.org/10.3892/ol.2024.14564
MLA
Tanaka, K., Yasuda, M., Tachi, T., Teshigawara, Y., Inoue, S., Ino, Y., Kitagawa, J., Noguchi, Y., Yoshimura, T., Teramachi, H., Kasahara, S."Quality of life assessment and cost‑utility analysis of initial chemotherapy for patients with non‑Hodgkin's lymphoma: A prospective analysis". Oncology Letters 28.3 (2024): 430.
Chicago
Tanaka, K., Yasuda, M., Tachi, T., Teshigawara, Y., Inoue, S., Ino, Y., Kitagawa, J., Noguchi, Y., Yoshimura, T., Teramachi, H., Kasahara, S."Quality of life assessment and cost‑utility analysis of initial chemotherapy for patients with non‑Hodgkin's lymphoma: A prospective analysis". Oncology Letters 28, no. 3 (2024): 430. https://doi.org/10.3892/ol.2024.14564